Induced pluripotent stem cells (iPSC)

01Overview and value chain#

Markers EC: FDA/EMA IND frameworks for iPSC-derived therapies + ICH S5(R3) developmental toxicology | OECD: Biotech & health | Regulator: FDA (USA), EMA (EU), MOA (China)

An induced pluripotent stem cell is an adult cell reprogrammed backward into an embryonic-like state: it self-renews indefinitely and, on instruction, differentiates into any tissue in the body. The reprogramming solved regenerative medicine’s supply problem — a pluripotent line no longer requires an embryo, and a single engineered master line becomes the feedstock for standardized batches of therapeutic cells rather than one patient’s bespoke product. The corpus’s ledger evidence shows that platform logic operating at three altitudes. Fate Therapeutics runs the product end: iPSC-derived NK cells expanded from one master line into standardized GMP batches, backed by $205.1 million of cash and investments as of December 2025, a 40,000-plus square foot San Diego manufacturing facility, a California drug manufacturing license, FDA IND clearances, and MHRA and EMA authorizations. Defined Bioscience runs the substrate end: the HiDef media line — including S8 stem-cell suspension medium and a DMEM/F12 basal tested across more than 100 hiPSC and hESC lines — is the defined culture chemistry every standardized batch depends on, built on a $1.5 million NIH SBIR grant (2022) and seed rounds. Cyprotex runs the safety-science end, inside Labcorp: devTOX quickPredict applies human iPSCs to developmental toxicology with an FDA-agreed Context of Use under ICH S5(R3). The boundary drawn here: this page owns the iPSC platform — reprogramming, defined media, expansion, assay — while the clinical applications belong to sibling pages.

Key directions of induced pluripotent stem cells:

1. Master-line banking for off-the-shelf therapy (One Line, Many Doses): Fate Therapeutics’ iPSC-NK platform manufactures standard batches from a single engineered line — the repeatable-product answer to patient-specific manufacturing.
2. Defined culture media (Chemistry of Self-Renewal): HiDef S8 suspension medium and tested DMEM/F12 basal formulations remove undefined components from the growth of 100-plus stem-cell lines.
3. Human-iPSC toxicology (Assay Replacement): devTOX quickPredict predicts developmental toxicity in human cells with an FDA-agreed Context of Use — an animal-study replacement grounded in ICH S5(R3).
4. Platform standardization (From Craft to Process): the reprogramming-to-batch chain turns stem-cell science into a licensed, inspected manufacturing operation.

Sectoral value chain#

[adult cell / biopsy] ──> [reprogramming] ──> [master iPSC line]
                                                        │
                                            (defined media, QC release)
                                                        ▼
[assay or therapy] <── [differentiation / expansion] <── [characterized bank]

Value chain levels#

Cross-cutting technologies of the sector:

• Master-cell-bank discipline (Banking and Release): the lot tree that keeps every dose traceable to one characterized line.
• Chemically defined media (Xeno-Free Formulations): formulations that remove serum and feeder variability from expansion.
• Directed differentiation protocols (Lineage Guides): published, reproducible recipes that turn pluripotent biomass into NK cells, neurons or cardiomyocytes.

02US#

The US carries both the manufacturing end and the media end of the platform in this corpus’s evidence.

San Diego’s iPSC cluster, NIH-backed media, FDA IND clearances#

• Fate Therapeutics (San Diego): $205.1 million in cash and investments as of December 2025; a 40,000-plus square foot GMP facility designed to support all clinical phases; a California drug manufacturing license; multiple FDA-cleared INDs.
• Defined Bioscience (San Diego): founded 2020, $1.5 million NIH SBIR funding in 2022 plus seed rounds; HiDef media tested across more than 100 hiPSC and hESC lines.
• FDA as reference reviewer: IND clearances and the devTOX Context of Use both anchor US regulatory acceptance of iPSC-derived products.

03CN#

China’s stem-cell therapy work runs under clinical-research rules administered through hospital programs; the corpus’s ledger depth there has not reached this node, so this section records structure rather than vendor claims.

Stem-cell clinical research rules, hospital programs, MOA/NMPA boundary#

• Clinical research administration: iPSC therapy candidates enter through hospital-based research programs ahead of product registration.
• Registration boundary: therapeutic and research uses split across regulator portfolios, with MOA relevant to feed-adjacent applications.
• Ledger gap: no sourced CN iPSC-platform dossiers exist yet — a screen-wave target.

04EU#

Europe contributes the toxicology-science angle: a UK-headquartered Labcorp subsidiary turned human iPSCs into a regulatory-grade developmental-toxicology assay.

ICH S5(R3) alignment, UK testing sites, FDA-agreed Context of Use#

• Cyprotex (Macclesfield and Alderley Park, UK): the in-vitro ADMET and high-content toxicology platform, with US sites in Watertown, Massachusetts and Kalamazoo, Michigan.
• devTOX quickPredict: human-iPSC developmental toxicology with an FDA-agreed Context of Use statement, compliant with the ICH S5(R3) definition.
• Founded 1999 heritage: the assay business predates the iPSC era and converted its legacy screen portfolio to human-cell methods.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack runs from one donor sample to one licensed product line — and every stage exists to remove a source of variability.

1. Master-line banking (One Line, Many Batches):
   • a characterized master iPSC line is the fixed reference every batch descends from.
   • case: Fate Therapeutics’ single-line iPSC-NK manufacturing, licensed by the State of California.
2. Defined media chemistry (HiDef Formulations):
   • chemically specified media remove serum and feeder variability from expansion.
   • case: Defined Bioscience’s HiDef S8 suspension medium validated across more than 100 hiPSC and hESC lines.
3. Human-assay conversion (Cells Replace Animals):
   • iPSC-derived developmental assays convert animal studies into human-cell tests with agreed regulatory contexts.
   • case: Cyprotex’s devTOX quickPredict — FDA-agreed Context of Use under ICH S5(R3).

07Value chains and production pipelines#

Industrial pipeline of an iPSC product line (GMP master-bank regime)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Donor biopsy           │ ───> │ 2. Reprogramming          │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Differentiation        │ <─── │ 3. Master bank + media    │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Assay / GMP batch      │ ───> │ 6. Regulatory release     │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Donor biopsy

A screened donor sample supplies the somatic cells that reprogramming will reset.

Stage 2: Reprogramming

Reset factors drive the adult cell back to pluripotency; candidate lines are karyotyped and pluripotency-certified.

Stage 3: Master bank and defined culture

Certified lines enter a master bank and expand in chemically defined media — the HiDef-class step that makes batches comparable.

Stage 4: Differentiation

Directed protocols convert pluripotent biomass into NK cells or other target lineages for therapy and assay use.

Stage 5: Assay and GMP batch

Differentiated cells become either regulatory-grade toxicology assays or GMP-filled therapeutic doses.

Stage 6: Regulatory release

IND frameworks and ICH-aligned toxicology contexts convert the batch into a deployed product.